Last reviewed 2026-05-23 · How we verify

Rimoterol (RIMITEROL)

Phase 2 active Small molecule Under review Quality 0/100

Rimoterol (generic name: RIMITEROL) is a rimiterol drug. It is currently in Phase 2 development.

Rimiterol works by binding to and activating a specific receptor in the body, which helps to regulate various physiological processes.

Rimiterol is a small molecule that acts as a beta-2 adrenergic receptor agonist. It belongs to the drug class of agonists, specifically targeting the beta-2 adrenergic receptor.

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	RIMITEROL
Drug class	rimiterol
Modality	Small molecule
Therapeutic area	Other
Phase	Phase 2

Mechanism of action

Imagine your body's cells are like locks, and rimiterol is a key that fits into a specific lock. When it binds to the lock, it sends a signal that helps to calm down or stimulate certain bodily functions, depending on the condition being treated.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Rimoterol CI brief — competitive landscape report
Rimoterol updates RSS · CI watch RSS

Frequently asked questions about Rimoterol

What is Rimoterol?

Rimoterol (RIMITEROL) is a rimiterol drug.

How does Rimoterol work?

Rimiterol works by binding to and activating a specific receptor in the body, which helps to regulate various physiological processes.

What is the generic name of Rimoterol?

RIMITEROL is the generic (nonproprietary) name of Rimoterol.

What drug class is Rimoterol in?

Rimoterol belongs to the rimiterol class. See all rimiterol drugs at /class/rimiterol.

What development phase is Rimoterol in?

Rimoterol is in Phase 2.

Drug class: All rimiterol drugs
Therapeutic area: All drugs in Other

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing